TELA Bio
TELA
22 hedge funds and large institutions have $82.7M invested in TELA Bio in 2019 Q4 according to their latest regulatory filings, with 22 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
55.95% more ownership
Funds ownership: 0% → 55.95% (+56%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$37M |
| 2 |
RI
RTW Investments
New York
|
+$13.9M |
| 3 |
EWM
Essex Woodlands Management
The Woodlands,
Texas
|
+$9.41M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$4.89M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.46M |
Top Sellers
TELA Hedge Fund Activity: Q4 2019 in Review
22 of the 5,092 institutional investors tracked by Wall St. Rank reported a position in TELA Bio (TELA) for Q4 2019, worth a combined $82.7M.
Buyers outnumbered sellers: 22 funds opened new TELA positions and 0 closed out — a net gain of 22 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $37M.
- 22 institutional investors held TELA Bio (TELA) as of Q4 2019, up from 0 in Q3 2019.
- Funds reported $82.7M of TELA Bio stock for Q4 2019.
- 22 funds opened new TELA Bio positions in Q4 2019 and 0 closed out, a net change of +22 holders.
- The largest TELA Bio buyer in Q4 2019 was OrbiMed, an estimated $37M added.
Based on aggregated 13F filings for Q4 2019.